In The News

    • MAY 29 2019

    BioSpace: ASCO 2019 Preview: Presentations to Keep An Eye On

    Oncoceutics, Inc. – Philadelphia-based Oncoceutics, Inc. will showcase data from its ongoing trial assessing ONC201 in adult recurrent H3 K27M-mutant glioma. The oral abstract session presentation, entitled “Single agent ONC201 in adult recurrent H3 K27M-mutant glioma” will describe the clinical experience of ONC201, in adults with recurrent H3 K27M-mutant glioma. ONC201 is an orally active

    • MAY 28 2019

    United States Patent and Trademark Office Issues Patents to Oncoceutics

    Earlier this month Oncoceutics confirmed that the United States Patent and Trademark Office (USPTO) has issued patent to the company with an expiration date of January 29, 2036. This newly issued patent covers the composition of matter for ONC213, its di-salt formulation, and its use in the treatment of cancer. In addition to the claims related to